Bulletin
Investor Alert

Illumina Inc.

NAS: ILMN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 26, 2021, 4:03 p.m.

/zigman2/quotes/203509482/composite

$

369.79

Change

0.00 0.00%

Volume

Volume 33,552

Quotes are delayed by 20 min

/zigman2/quotes/203509482/composite

Previous close

$ 365.56

$ 369.79

Change

+4.23 +1.16%

Day low

Day high

$367.44

$376.35

Open

52 week low

52 week high

$311.02

$555.77

Open

Alex Aravanis

Alex Aravanis founded GRAIL, Inc. He is Chief Technology Officer & Senior Vice President of Illumina, Inc. He is also Fellow at National Institutes of Health.

Dr. Aravanis previously was Chief Science Officer at Sapphire Energy, Inc., Chief Scientific Officer at GRAIL, Inc., Principal at HP, Inc., Vice President-Engineering for Pria Diagnostics LLC, Principal at Lawrence Berkeley National Laboratory, Fellow at The National Science Foundation, Principal at Stanford University and Fellow at The Helen Hay Whitney Foundation.

He received a doctorate and a graduate degree from Stanford University and an undergraduate degree from Berkeley Law University of California.

Transactions

Date Shares Transaction Value
11/12/2021 361   Disposition at $386.35 per share. 139,473
11/05/2021 191   Derivative/Non-derivative trans. at $408.14 per share. 77,955
11/02/2021 483   Disposition at $417.62 per share. 201,711
11/02/2021 200   Disposition at $416.48 per share. 83,296
11/02/2021 393   Disposition at $413.24 per share. 162,404
11/02/2021 366   Disposition at $412.15 per share. 150,847
11/02/2021 645   Disposition at $411.47 per share. 265,399
11/02/2021 639   Disposition at $410.47 per share. 262,291
11/02/2021 200   Disposition at $409.28 per share. 81,856
10/26/2021 2,926   Disposition at $423 per share. 1,237,698
10/19/2021 173   Disposition at $414.7 per share. 71,744
10/19/2021 154   Disposition at $413.52 per share. 63,683
10/19/2021 1,051   Disposition at $412.28 per share. 433,307
10/19/2021 948   Disposition at $411.38 per share. 389,989
10/19/2021 600   Disposition at $410.42 per share. 246,252
10/12/2021 151   Disposition at $411.22 per share. 62,095
10/12/2021 709   Disposition at $410.52 per share. 291,059
10/12/2021 893   Disposition at $409.48 per share. 365,666
10/12/2021 750   Disposition at $408.33 per share. 306,248
10/12/2021 423   Disposition at $407.29 per share. 172,284
08/18/2021 9,949   Derivative/Non-derivative trans. at $510.61 per share. 5,080,059
08/18/2021 21,653   Award at $510.61 per share. 11,056,238
02/09/2021 2,208   Award at $0 per share. 0
07/06/2020 3,295   Award at $0 per share. 0

Officers and Executives

Mr. Francis A. deSouza
President, Chief Executive Officer & Director
Mr. Robert P. Ragusa
Chief Operations Officer
Mr. Sam A. Samad
Chief Financial Officer & Senior Vice President
Dr. Alex Aravanis
CTO, Head-Research & Product Development
Mr. Steve Phillpott
Chief Information Officer & Senior Vice President
Dr. Phillip G. Febbo
Chief Medical Officer
Dr. Joydeep Goswami
SVP-Corporate Development & Strategic Planning
Mr. Min-Jui Shen
Director-Scientific Operations & Research
Ms. Susan H. Tousi
Chief Commercial Officer
Mr. Charles E. Dadswell
Secretary, Senior VP & Compliance Officer
Ms. Paula Lynn Dowdy
SVP & GM-Commercial Operations, Europe
Ms. Kathy Reeves
Chief Marketing Officer
Mr. Jose A. Torres
Chief Accounting Officer & Vice President
Ms. Juliet C. Cunningham
Vice President-Investor Relations
Ms. Aimee Hoyt
Chief People Officer & Senior Vice President
Dr. John Wendell Thompson
Chairman
Dr. Scott Gottlieb
Independent Director
Dr. Robert S. Epstein
Independent Director
Dr. Frances Hamilton Arnold
Independent Director
Mr. Philip W. Schiller
Independent Director
Ms. Caroline D. Dorsa
Independent Director
Dr. Gary S. Guthart
Independent Director
Ms. Susan E. Siegel
Independent Director
Link to MarketWatch's Slice.